Asset
IBREXAFUNGERP
Revenue
No revenue reported in loaded filings.
Clinical trials (6)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05178862 | phase3 | terminated | 2022-08-03 | 2025-11-07 | Scynexis, Inc. | A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole |
| NCT03253094 | phase2 | completed | 2017-08-01 | 2018-05-04 | Scynexis, Inc. | Dose-Finding Study of Oral Ibrexafungep (SCY-078) vs. Oral Fluconazole in Subjects With Acute Vulvovaginal Candidiasis |
| NCT03672292 | phase2 | terminated | 2019-01-22 | 2023-03-27 | Scynexis, Inc. | Evaluate Safety and Efficacy of the Coadministration of Ibrexafungerp With Voriconazole in Patients With Invasive Pulmonary Aspergillosis |
| NCT03363841 | phase3 | completed | 2017-11-15 | 2023-04-14 | Scynexis, Inc. | Open-Label Study to Evaluate the Efficacy and Safety of Oral Ibrexafungerp (SCY-078) in Patients With Candidiasis Caused by Candida Auris (CARES) |
| NCT02244606 | phase2 | completed | 2014-09-01 | 2016-06-01 | Scynexis, Inc. | Oral Ibrexafungerp (SCY-078) vs Standard-of-Care Following IV Echinocandin in the Treatment of Invasive Candidiasis |
FDA applications (0)
This company has no applications containing this asset.